Speaker Profile
Ph.D., CEO, GeneCentric Tx
Biography
Mike is a biotechnology executive and scientist with a passion for translating innovative science into transformative healthcare solutions and commercial opportunities. With over two decades of leadership in start-ups and pharmaceutical giants, Mike has spearheaded the development of world-class therapeutics, companion diagnostics, and precision medicine platforms that have redefined patient care.
Talk
Advancing AI Algorithm Development For Liquid Biopsy
Liquid biopsy is a fast-growing, multi-billion-dollar market, but current assays miss critical biology hidden in gene expression. Most tests rely solely on static DNA alterations. We’ve added dynamic gene expression – turning passive genomic data into active, intelligent data to overcome current limitations in liquid biopsies for precision oncology.
Clinical Dx Showcase:
GeneCentric Therapeutics
GeneCentric’s mission is to address the urgent unmet need in precision oncology for better biomarkers and to bring these biomarkers to blood testing. Through AI and the inherent multimodal output of our GenomicsNext™ platform, we are accelerating advancements in cancer genomics.
Session Abstract – PMWC 2026 Silicon Valley
The PMWC 2026 Data Applications in Clinical Diagnostics Showcase will provide a 15-30 minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.
- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Neurodegenerative
